Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00110747 · ClinicalTrials.gov registry record · Phase 3
S-Caine™ Peel (Skin Numbing Cream) to Treat Pain During Non-Ablative Facial Laser Resurfacing in Adults
A Phase 3 study, sponsored by ZARS Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 54
- Enrollment target
NCT00110747: Completed Phase 3 study, sponsored by ZARS Pharma.
NCT00110747 is a Phase 3 study that has completed, run by ZARS Pharma. The registered enrollment target is 54 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00110747, a Phase 3 study, has completed, sponsored by ZARS Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 54 participants
- Enrollment target
Study Summary
Lasers are used for non-ablative resurfacing of facial rhytides, atrophic scars, and a variety of epidermal and dermal lesions. Pain associated with the non-ablative laser treatment has been described as moderate to severe. For this reason, local anesthesia is commonly used to eliminate or minimize the pain. S-Caine™ Peel (lidocaine 7% and tetracaine 7% cream) is a eutectic formulation of lidocaine and tetracaine. The purpose of this study is to evaluate if S-Caine Peel is effective in providing topical local dermal anesthesia for non-ablative facial laser resurfacing in adults.
Primary Outcome
Patient's evaluation of pain using a 100 mm Visual Analog scale (VAS)
Interventions
- DRUG Placebo Peel
- DRUG S-Caine™ Peel (lidocaine and tetracaine topical cream 7%/7%)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2005-06 |
| Est. Completion | 2005-09 |
| Phase | Phase 3 |
What the finished NCT00110747 record still lists
NCT00110747 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo Peel is the first listed.
NCT00110747 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00110747 about?
NCT00110747 is a clinical study titled "S-Caine™ Peel (Skin Numbing Cream) to Treat Pain During Non-Ablative Facial Laser Resurfacing in Adults". Lasers are used for non-ablative resurfacing of facial rhytides, atrophic scars, and a variety of epidermal and dermal lesions. Pain associated with the non-ablative laser treatment has been described as moderate to severe. For this reason, local anesthesia is commonly used to eliminate or minimize ...
What is the current status of trial NCT00110747?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 54 participants. The study started on 2005-06. Estimated completion is 2005-09.
What interventions are being tested in trial NCT00110747?
The interventions under investigation include: Placebo Peel (DRUG), S-Caine™ Peel (lidocaine and tetracaine topical cream 7%/7%) (DRUG).
Who is sponsoring clinical trial NCT00110747?
This trial is sponsored by ZARS Pharma, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00110747's enrollment target sits among peer trials
54 1838th of 2000 higher than 162 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia